ID: ALA3134465

Max Phase: Preclinical

Molecular Formula: C21H20ClN3O6S

Molecular Weight: 477.93

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC[C@H]1CN(c2ccc(N3CCC(C(=O)O)CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1

Standard InChI:  InChI=1S/C21H20ClN3O6S/c22-17-6-5-16(32-17)19(27)23-10-15-11-25(21(30)31-15)14-3-1-13(2-4-14)24-8-7-12(20(28)29)9-18(24)26/h1-6,12,15H,7-11H2,(H,23,27)(H,28,29)/t12?,15-/m0/s1

Standard InChI Key:  DKZVDNUNOWIRLO-CVRLYYSRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 477.93

Molecular Weight (Monoisotopic): 477.0761

AlogP: 2.98

#Rotatable Bonds: 6

Polar Surface Area: 116.25

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.92

CX Basic pKa:

CX LogP: 2.14

CX LogD: -1.06

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.66

Np Likeness Score: -1.53

References

1. Trstenjak U, Ilas J, Kikelj D.  (2014)  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety,  5  (2): [10.1039/C3MD00250K]

Source

Source(1):

• Scientific Literature